1,196 research outputs found
Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of Treatment
While persistent T-cell activation has been cross-sectionally associated with poor CD4+ T-cell restoration in HIV-infected individuals maintaining antiretroviral treatment (ART)–mediated viral suppression, it remains unclear whether CD8+ T-cell activation is of predictive effect on CD4+ T-cell recovery
Immunoprecipitation of spliceosomal RNAs by antisera to galectin-1 and galectin-3
We have shown that galectin-1 and galectin-3 are functionally redundant splicing factors. Now we provide evidence that both galectins are directly associated with spliceosomes by analyzing RNAs and proteins of complexes immunoprecipitated by galectin-specific antisera. Both galectin antisera co-precipitated splicing substrate, splicing intermediates and products in active spliceosomes. Protein factors co-precipitated by the galectin antisera included the Sm core polypeptides of snRNPs, hnRNP C1/C2 and Slu7. Early spliceosomal complexes were also immunoprecipitated by these antisera. When splicing reactions were sequentially immunoprecipitated with galectin antisera, we found that galectin-1 containing spliceosomes did not contain galectin-3 and vice versa, providing an explanation for the functional redundancy of nuclear galectins in splicing. The association of galectins with spliceosomes was (i) not due to a direct interaction of galectins with the splicing substrate and (ii) easily disrupted by ionic conditions that had only a minimal effect on snRNP association. Finally, addition of excess amino terminal domain of galectin-3 inhibited incorporation of galectin-1 into splicing complexes, explaining the dominant-negative effect of the amino domain on splicing activity. We conclude that galectins are directly associated with splicing complexes throughout the splicing pathway in a mutually exclusive manner and they bind a common splicing partner through weak protein–protein interactions
Miscarriage and stillbirth following maternal Zika virus infection in nonhuman primates.
Zika virus (ZIKV) infection is associated with congenital defects and pregnancy loss. Here, we found that 26% of nonhuman primates infected with Asian/American ZIKV in early gestation experienced fetal demise later in pregnancy despite showing few clinical signs of infection. Pregnancy loss due to asymptomatic ZIKV infection may therefore be a common but under-recognized adverse outcome related to maternal ZIKV infection
Taking the Measure of the Universe: Precision Astrometry with SIM PlanetQuest
Precision astrometry at microarcsecond accuracy has application to a wide
range of astrophysical problems. This paper is a study of the science questions
that can be addressed using an instrument that delivers parallaxes at about 4
microarcsec on targets as faint as V = 20, differential accuracy of 0.6
microarcsec on bright targets, and with flexible scheduling. The science topics
are drawn primarily from the Team Key Projects, selected in 2000, for the Space
Interferometry Mission PlanetQuest (SIM PlanetQuest). We use the capabilities
of this mission to illustrate the importance of the next level of astrometric
precision in modern astrophysics. SIM PlanetQuest is currently in the detailed
design phase, having completed all of the enabling technologies needed for the
flight instrument in 2005. It will be the first space-based long baseline
Michelson interferometer designed for precision astrometry. SIM will contribute
strongly to many astronomical fields including stellar and galactic
astrophysics, planetary systems around nearby stars, and the study of quasar
and AGN nuclei. SIM will search for planets with masses as small as an Earth
orbiting in the `habitable zone' around the nearest stars using differential
astrometry, and could discover many dozen if Earth-like planets are common. It
will be the most capable instrument for detecting planets around young stars,
thereby providing insights into how planetary systems are born and how they
evolve with time. SIM will observe significant numbers of very high- and
low-mass stars, providing stellar masses to 1%, the accuracy needed to
challenge physical models. Using precision proper motion measurements, SIM will
probe the galactic mass distribution and the formation and evolution of the
Galactic halo. (abridged)Comment: 54 pages, 28 figures, uses emulateapj. Submitted to PAS
Pediatric lung transplantation: The years 1985 to 1992 and the clinical trial of FK 506
The application of lung transplantation to the pediatric population was a natural extension of the success realized in our adult transplantation program, which began in 1982. Twenty pediatric patients (age range 3 to 18 years) have had heart-lung (n = 11), double lung (n = 8), and single lung (n = 1) transplantation procedures. The causes of end-stage lung disease were primary pulmonary hypertension (n = 7), congenital heart disease (n = 5), cystic fibrosis (n = 4), pulmonary arteriovenous malformation (n = 2), graft- versus-host disease (n = 1), and desquamative interstitial pneumonitis (n = 1). Four (20%) patients had thoracic surgical procedures before the transplantation operation. The survival was 80% at a mean follow-up of 2 years. Immunosuppressive drugs included cyclosporine (n = 9) or FK 506 (n = 11) based therapy with azathioprine and steroids. Children were followed up by means of spirometry, transbronchial biopsy, and primed lymphocyte testing of bronchoalveolar lavage fluid. The mean number of treated episodes of rejection was 1.4 at 30 days, 0.5 at 30 to 90 days, and 1.4 at more than 90 days, and the first treated rejection episode occurred on average 28 days after the operation. Obliterative bronchiolitis developed in four (25%) of 16 patients surviving more than 100 days. Results of pulmonary function tests have remained good in almost all recipients. The greatest infectious risk was that of cytomegalovirus: one death and one case of pneumonia. Posttransplantation lymphoproliferative disease was diagnosed in two (12.5%) patients; both recovered. The most common complications were hypertension (25%) and postoperative bleeding (15%). Early results indicate that lung transplantation is a most promising therapy for children with severe vascular and parenchymal lung disease
Recommended from our members
The Back Pain Consortium (BACPAC) Research Program Data Harmonization: Rationale for Data Elements and Standards
ObjectiveOne aim of the Back Pain Consortium (BACPAC) Research Program is to develop an integrated model of chronic low back pain that is informed by combined data from translational research and clinical trials. We describe efforts to maximize data harmonization and accessibility to facilitate Consortium-wide analyses.MethodsConsortium-wide working groups established harmonized data elements to be collected in all studies and developed standards for tabular and nontabular data (eg, imaging and omics). The BACPAC Data Portal was developed to facilitate research collaboration across the Consortium.ResultsClinical experts developed the BACPAC Minimum Dataset with required domains and outcome measures to be collected by use of questionnaires across projects. Other nonrequired domain-specific measures are collected by multiple studies. To optimize cross-study analyses, a modified data standard was developed on the basis of the Clinical Data Interchange Standards Consortium Study Data Tabulation Model to harmonize data structures and facilitate integration of baseline characteristics, participant-reported outcomes, chronic low back pain treatments, clinical exam, functional performance, psychosocial characteristics, quantitative sensory testing, imaging, and biomechanical data. Standards to accommodate the unique features of chronic low back pain data were adopted. Research units submit standardized study data to the BACPAC Data Portal, developed as a secure cloud-based central data repository and computing infrastructure for researchers to access and conduct analyses on data collected by or acquired for BACPAC.ConclusionsBACPAC harmonization efforts and data standards serve as an innovative model for data integration that could be used as a framework for other consortia with multiple, decentralized research programs
Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy
Background: There is an unmet need for effective therapies for patients with advanced or
metastatic urothelial cancer who cannot tolerate cisplatin-based chemotherapy. Cisplatinineligible patients experience a high frequency of adverse events from the most commonly
used standard of care treatment, carboplatin plus gemcitabine, or alternative treatment with
gemcitabine monotherapy. Pembrolizumab is a potent, highly selective humanised monoclonal antibody that releases checkpoint inhibition of the immune response system, and provides
a new alternative for these patients.
Objective: To assess the cost-effectiveness of pembrolizumab for first-line treatment of
urothelial carcinoma ineligible for cisplatin-based therapy in patients with strongly PD-L1–
positive tumours in Sweden.
Design, setting, and participants: Parametric survival curves were fitted to overall
survival, progression-free survival, and time on treatment data from KEYNOTE-052 to extrapolate clinical outcomes. A simulated treatment comparison and a network meta-analysis were
conducted to estimate the comparative efficacy of pembrolizumab versus carboplatin plus
gemcitabine and gemcitabine monotherapy. EQ-5D data from KEYNOTE-052 were used to
estimate utility, while resource use and cost inputs were estimated using Swedish regional
pricing lists and clinician opinion.
Outcome measurements and statistical analysis: The model reported costs, life years,
and quality-adjusted life years (QALYs), and results were tested using deterministic and
probabilistic sensitivity analysis.
Results and limitations: We estimated that pembrolizumab would improve survival by
2.11 and 2.16 years and increase QALYs by 1.71 and 1.75 compared to carboplatin plus
gemcitabine and gemcitabine monotherapy, respectively. Pembrolizumab was associated with
a cost increase of s90 520 versus carboplatin plus gemcitabine and s95 055 versus gemcitabine,
with corresponding incremental cost-effectiveness ratios of s53 055/QALY and s54 415/QALY.
Conclusions: At a willingness-to-pay threshold of s100 000/QALY, pembrolizumab is a costeffective treatment versus carboplatin plus gemcitabine and versus gemcitabine.
Patient summary: This is the first analysis to show that pembrolizumab is a cost-effective
option for first-line treatment of cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma in Sweden
Integrative Analysis of the Mitochondrial Proteome in Yeast
In this study yeast mitochondria were used as a model system to apply, evaluate, and integrate different genomic approaches to define the proteins of an organelle. Liquid chromatography mass spectrometry applied to purified mitochondria identified 546 proteins. By expression analysis and comparison to other proteome studies, we demonstrate that the proteomic approach identifies primarily highly abundant proteins. By expanding our evaluation to other types of genomic approaches, including systematic deletion phenotype screening, expression profiling, subcellular localization studies, protein interaction analyses, and computational predictions, we show that an integration of approaches moves beyond the limitations of any single approach. We report the success of each approach by benchmarking it against a reference set of known mitochondrial proteins, and predict approximately 700 proteins associated with the mitochondrial organelle from the integration of 22 datasets. We show that a combination of complementary approaches like deletion phenotype screening and mass spectrometry can identify over 75% of the known mitochondrial proteome. These findings have implications for choosing optimal genome-wide approaches for the study of other cellular systems, including organelles and pathways in various species. Furthermore, our systematic identification of genes involved in mitochondrial function and biogenesis in yeast expands the candidate genes available for mapping Mendelian and complex mitochondrial disorders in humans
Effects of Genital Ulcer Disease and Herpes Simplex Virus Type 2 on the Efficacy of Male Circumcision for HIV Prevention: Analyses from the Rakai Trials
Ron Gray and colleagues analyze data from two circumcision trials in Uganda to assess how HSV-2 status and genital ulcer disease affect the procedure's ability to reduce HIV infection
Driving vascular endothelial cell fate of human multipotent Isl1+ heart progenitors with VEGF modified mRNA
Distinct families of multipotent heart progenitors play a central role in the generation of diverse cardiac, smooth muscle and endothelial cell lineages during mammalian cardiogenesis. The identification of precise paracrine signals that drive the cell-fate decision of these multipotent progenitors, and the development of novel approaches to deliver these signals in vivo, are critical steps towards unlocking their regenerative therapeutic potential. Herein, we have identified a family of human cardiac endothelial intermediates located in outflow tract of the early human fetal hearts (OFT-ECs), characterized by coexpression of Isl1 and CD144/vWF. By comparing angiocrine factors expressed by the human OFT-ECs and non-cardiac ECs, vascular endothelial growth factor (VEGF)-A was identified as the most abundantly expressed factor, and clonal assays documented its ability to drive endothelial specification of human embryonic stem cell (ESC)-derived Isl1+ progenitors in a VEGF receptor-dependent manner. Human Isl1-ECs (endothelial cells differentiated from hESC-derived ISL1+ progenitors) resemble OFT-ECs in terms of expression of the cardiac endothelial progenitor- and endocardial cell-specific genes, confirming their organ specificity. To determine whether VEGF-A might serve as an in vivo cell-fate switch for human ESC-derived Isl1-ECs, we established a novel approach using chemically modified mRNA as a platform for transient, yet highly efficient expression of paracrine factors in cardiovascular progenitors. Overexpression of VEGF-A promotes not only the endothelial specification but also engraftment, proliferation and survival (reduced apoptosis) of the human Isl1+ progenitors in vivo. The large-scale derivation of cardiac-specific human Isl1-ECs from human pluripotent stem cells, coupled with the ability to drive endothelial specification, engraftment, and survival following transplantation, suggest a novel strategy for vascular regeneration in the heart
- …